November 01, 2014

Partner Louis E. Fogel and Associate Chad J. Ray wrote an editorial for Informa Healthcare’s Expert Opinion on Therapeutic Patents journal.  Titled “Teva Pharmaceuticals v. Sandoz: Availability of Generic Glatiramer Acetate and the Impact to Patent Litigation Claim Construction,” the article examines the upcoming case of Teva Pharmaceuticals v. Sandoz before the U.S. Supreme Court.  The authors explain that the Court will address how much deference the appellate court should afford to a trial court's claim construction ruling.  They describe the background of the case and explore implications of the decision, which they suggest may be far-reaching because how claims are construed can determine whether a patent is infringed or not infringed, valid or invalid.